Team:Evry

From 2013.igem.org

(Difference between revisions)
 
(217 intermediate revisions not shown)
Line 1: Line 1:
-
{{:Team:Evry/head}}
+
{{:Team:Evry/template_home}}
<html>
<html>
-
 
-
<div id="maincontainer_evry2013">
 
-
<div class="navbar navbar-fixed-top">
 
-
<div class="navbar-inner">
 
-
    <center>
 
-
    <ul class="nav">
 
-
    <li><a class="home-link" href="https://2013.igem.org/Team:Evry">Home</a></li>
 
-
    <li><a class="project-link" href="https://2013.igem.org/Team:Evry/Project">Project</a></li>
 
-
    <li><a class="team-link" href="https://2013.igem.org/Team:Evry/Team">Team</a></li>
 
-
    <li><a class="model-link" href="https://2013.igem.org/Team:Evry/Modeling">Model</a></li>
 
-
    <li><a class="biology-link" href="https://2013.igem.org/Team:Evry/Biology">Biology</a></li>
 
-
    <li><a class="practice-link" href="https://2013.igem.org/Team:Evry/HumanPractice">Practice</a></li>
 
-
    <li><a class="notebook-link" href="https://2013.igem.org/Team:Evry/Notebook/w8">Notebook</a></li>
 
-
    <li><a class="ref-link" href="https://2013.igem.org/Team:Evry/References">References</a></li>
 
-
    <li><a class="spon-link" href="https://2013.igem.org/Team:Evry/Sponsors">Sponsors</a></li>
 
-
    </ul>
 
-
    </center>
 
-
</div></div>
 
<div id="mainTextcontainer">
<div id="mainTextcontainer">
-
<!--<a href='https://2013.igem.org/Team:Evry/Home' title='Vers la page française'> <img src='https://static.igem.org/mediawiki/2013/b/b9/Francais.jpg'/></a>-->
+
<h1>Welcome to the <b><span style="color:#bb8900">Iron Coli Project</span></b> Home Page</h1>
-
<h1 align='center'>Welcome to the Iron coli Project</h1>
+
<br />
-
<h2 align='center'>Abstract</h2>
+
<p align="center"><b>The aim of our team this year is to design and realize a <em>treatment for hemochromatosis and thalassemia</em> using synthetic biology with an <em>integrated human practice</em> and <em>modeling approach</em>. </b></p>
-
<p>
+
-
This year we choose to develop a project which deals with hematologic diseases. We focused specifically on diseases with an iron overload disorder. Among those type of diseases, we were interested in the hereditary hemochromatosis and hemosiderosis. In the case of hereditary hemochromatosis, the iron overload disorder is a direct consequence of this disease. While in the hemosiderosis the iron overload is due to a metabolic perturbation.
+
-
</p>
+
-
<p>
+
-
Today the iron overload can be treated by bloodletting in the case of the hemochromatosis but it cannot be used as a treatment of hemosiderosis because patients suffer of anaemia. In our project we want to solve this problem acting directly at the iron absorption source, in the intestines.
+
-
</p>
+
-
<p>
+
-
Using the Ferric Uptake Regulation (FUR) system to control siderophore (iron chelator) biosynthesis, we engineered bacteria giving them the ability to produce these siderophores in response of iron. In order to limit the iron overload in the patient, these bacteria will be placed in capsule and ingested during a meal. Arriving in the duodenum our bacteria will limit iron absorption by chelating it.
+
-
</p>
+
-
<h2 align='center'>Abstract vE</h2>
+
<br /><br />
-
<p>
+
 
-
This year, our project focuses on hematological disorders. More specifically, we focus on diseases that are subsequent to an iron overload such as hemochromatosis and thalassemia. For hereditary hemochromatosis, the symptoms are due to the overabsorption of iron from the duodenum by the mutation of the HFE protein. However, in case of thalassemia, patients excessively absorb iron because of a subsequent metabolic perturbation.
+
<div>
-
</p>
+
<div style="float:right;width:49%;margin-left:1%;">
 +
<h3 align="center">The Team</h3>
 +
<img src="https://static.igem.org/mediawiki/2013/8/89/IronColiTeamatthejamboree.jpg" alt="team photo" width="100%"/>
 +
</div>
 +
</div>
 +
 
 +
<h3 align="center">Abstract</h3>
<p>
<p>
-
Nowadays, the iron overload is mainly treated by bloodlettings for hemochromatosic patients but cannot be extended to thalassemic patients who suffer from anaemia. Our project focuses on preventing the intestinal absorption of iron, thus acting directly at the source.
+
Our project focuses on developing a novel treatment for <a href="https://2013.igem.org/Team:Evry/Project_diseases"><em>hematological disorders</em></a>  caused by an <a href="https://2013.igem.org/Team:Evry/Project_metabolism"><em>iron overload</em></a>, such as hemochromatosis and thalassemia. These autosomal recessive disorders have symptoms including cirrhosis, arthritis, and heart failure, which result from overabsorption of iron from the duodenum. Although these are among the most common heritable diseases, treatment options are limited. Even today patients are mostly treated by frequent bloodletting, which <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions"><em>many people cannot support</em></a>. The aim of our project is to combat these diseases at the source by developing a therapy that prevents the intestinal absorption of iron.
</p>
</p>
<p>
<p>
-
Using the Ferric Uptake Regulation (FUR) system that controls siderophore biosynthesis (iron chelator), we engineer Escherichia coli in order to produce these siderophores in response of high concentrations of iron. To reduce the patient's iron absorption, our bacteria is placed in a capsule and will be ingested during a meal. Once arrived in the duodenum, our bacteria produce the siderophore at their full potential and chelate the iron.
+
We engineer the <i>Escherichia coli</i> <a href="https://2013.igem.org/Team:Evry/Project_FUR"><em>Ferric Uptake Regulation</em></a> (FUR) system using a <a href="https://2013.igem.org/Team:Evry/Inverter"><em>genetic inverter</em></a> so that they produce siderophores (<a href="https://2013.igem.org/Team:Evry/Chelator"><em>iron chelators</em></a>) in response of high concentrations of iron. These engineered bacteria are delivered to the patient's intestine by encapsulating them in an ingestible polymer (<a href="https://2013.igem.org/Team:Evry/Pill_design"><em>capsule</em></a>)  that specifically degrades in the duodenum. Once released into the intestine, the bacteria respond to ambient iron by secreting elevated levels of siderophores, thereby chelating the iron to prevent its absorption by the patient.
</p>
</p>
 +
 +
<script type="text/javascript" src="https://2012.igem.org/Team:Evry/wz_jsgraphics.js?action=raw"></script>
 +
<script type="text/javascript" src="https://2012.igem.org/Team:Evry/mapper.js?action=raw"></script>
 +
 +
<div style="clear:both;"></div>
 +
 +
<h3 align="center">Overview of the project and the achievements</h3>
 +
 +
<center>
 +
<div align="center">
 +
<img align="center" id="ModMap" src="https://static.igem.org/mediawiki/2013/4/4d/IGEM_Timeline.png" width="850" class="mapper" usemap="#overview_link" style="z-index:500;"/>
 +
 +
<map name="overview_link">
 +
<area shape="rect" coords="60,61,210,82" target="Project FUR" href="https://2013.igem.org/Team:Evry/Project_FUR" />
 +
<area shape="rect" coords="60,82,210,103" target="Results" href="https://2013.igem.org/Team:Evry/Results" />
 +
<area shape="rect" coords="60,103,210,124" target="Results" href="https://2013.igem.org/Team:Evry/Results#AceB_GFP" />
 +
<area shape="rect" coords="228,63,378,82" target="Inverter" href="https://2013.igem.org/Team:Evry/Inverter" />
 +
<area shape="rect" coords="228,101,378,120" target="Model"  nohref="nohref" />
 +
<area shape="rect" coords="228,82,378,101" target="Results" href="https://2013.igem.org/Team:Evry/Results#Inverter" />
 +
<area shape="rect" coords="399,63,556,80" target="Chelator" href="https://2013.igem.org/Team:Evry/Chelator" />
 +
<area shape="rect" coords="399,103,556,120" target="Results" href="https://2013.igem.org/Team:Evry/Chelator#caracterization_siderophore" />
 +
<area shape="rect" coords="399,83,556,100" target="Chelator" href="https://2013.igem.org/Team:Evry/Chelator#Second_design" />
 +
<area shape="rect" coords="633,76,841,94" target="Expert consultation" href="https://2013.igem.org/Team:Evry/HumanPractice/Expert_consultation" />
 +
<area shape="rect" coords="633,156,841,174" target="Philosophy" href="https://2013.igem.org/Team:Evry/Philosophy" />
 +
<area shape="rect" coords="633,136,841,154" target="Safety" href="https://2013.igem.org/Team:Evry/Safety" />
 +
<area shape="rect" coords="633,116,841,134" target="Seminar" href="https://2013.igem.org/Team:Evry/Seminar" />
 +
<area shape="rect" coords="633,96,841,114" target="Patients perceptions" href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" />
 +
 +
<!--
 +
<area shape="rect" coords="443,457,659,474"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
 +
<area shape="rect" coords="443,517,659,547"  href="https://2013.igem.org/Team:Evry/Model1#Conclusion" />
 +
<area shape="rect" coords="443,497,659,514"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
 +
<area shape="rect" coords="443,477,659,494"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
 +
<area shape="rect" coords="164,398,419,414"  href="https://2013.igem.org/Team:Evry/Model3#Description" />
 +
<area shape="rect" coords="164,458,419,474"  href="https://2013.igem.org/Team:Evry/Model3#Conclusion" />
 +
<area shape="rect" coords="164,438,419,454"  href="https://2013.igem.org/Team:Evry/Metabolism_model" />
 +
<area shape="rect" coords="164,418,419,434"  href="https://2013.igem.org/Team:Evry/Model3#Results" />
 +
-->
 +
 +
<area shape="rect" coords="118,276,283,294"  target="Norms from the European Pharmacopeoa" href="https://2013.igem.org/Team:Evry/Pill_design#norm" />
 +
<area shape="rect" coords="118,296,283,314"  target="Overcoming the acidity" href="https://2013.igem.org/Team:Evry/Pill_design#acidity" />
 +
<area shape="rect" coords="303,276,497,294"  target="Dissolution in the jejunum" href="https://2013.igem.org/Team:Evry/Pill_design#jejunum"/>
 +
<area shape="rect" coords="303,294,497,312"  target="Survival after the process" href="https://2013.igem.org/Team:Evry/Pill_design#conclusion" />
 +
 +
<area shape="rect" coords="631,175,794,195" href="https://2013.igem.org/Team:Evry/Economy" />
 +
<area shape="rect" coords="159,402,448,423" href="https://2013.igem.org/Team:Evry/Modelmeta1" />
 +
<area shape="rect" coords="159,443,448,464" href="https://2013.igem.org/Team:Evry/Metabolism_model" />
 +
<area shape="rect" coords="159,381,448,402" href="https://2013.igem.org/Team:Evry/Modelmeta2" />
 +
<area shape="rect" coords="159,422,448,443" href="https://2013.igem.org/Team:Evry/Modelmeta3" />
 +
<area shape="rect" coords="159,463,448,484" href="https://2013.igem.org/Team:Evry/pop_scale" />
 +
<area shape="rect" coords="159,483,448,504" href="https://2013.igem.org/Team:Evry/Modelmeta3" />
 +
 +
<area shape="rect" coords="462,464,595,484" href="https://2013.igem.org/Team:Evry/Modeltr1" />
 +
<area shape="rect" coords="462,484,595,504" href="https://2013.igem.org/Team:Evry/Modeltr1" />
 +
<area shape="rect" coords="462,504,595,524" href="https://2013.igem.org/Team:Evry/Modeltr2" />
 +
<area shape="rect" coords="464,524,673,558" href="https://2013.igem.org/Team:Evry/Modeltr2" />
 +
 +
</map>
</div>
</div>
 +
</center>
 +
 +
 +
<div style="clear:both;">
 +
</div>
</div>
 +
 +
</div>
 +
</div>
 +
 +
<!--
 +
<script type="text/javascript">
 +
alert("Our team is proud to announce that we were awarded a gold medal and the Best Human Practice price at the european jamboree! We are going to Boston.\n\nUnfortunately, we are missing a few thousands of euros to be capable of finishing the competition. If you are a company and would like to sponsor our team, please contact us at igemevry@gmail.com.")
 +
</script>
 +
-->
 +
</html>
</html>
{{:Team:Evry/foot}}
{{:Team:Evry/foot}}

Latest revision as of 18:38, 28 October 2013

Iron coli project

Welcome to the Iron Coli Project Home Page


The aim of our team this year is to design and realize a treatment for hemochromatosis and thalassemia using synthetic biology with an integrated human practice and modeling approach.



The Team

team photo

Abstract

Our project focuses on developing a novel treatment for hematological disorders caused by an iron overload, such as hemochromatosis and thalassemia. These autosomal recessive disorders have symptoms including cirrhosis, arthritis, and heart failure, which result from overabsorption of iron from the duodenum. Although these are among the most common heritable diseases, treatment options are limited. Even today patients are mostly treated by frequent bloodletting, which many people cannot support. The aim of our project is to combat these diseases at the source by developing a therapy that prevents the intestinal absorption of iron.

We engineer the Escherichia coli Ferric Uptake Regulation (FUR) system using a genetic inverter so that they produce siderophores (iron chelators) in response of high concentrations of iron. These engineered bacteria are delivered to the patient's intestine by encapsulating them in an ingestible polymer (capsule) that specifically degrades in the duodenum. Once released into the intestine, the bacteria respond to ambient iron by secreting elevated levels of siderophores, thereby chelating the iron to prevent its absorption by the patient.

Overview of the project and the achievements